MH4 TREATMENT COST AND COMORBIDITIES ASSOCIATEDWITH OBESITY AMONG CHILDREN ANDADOLESCENTSWITH BIPOLAR DISORDER  by Guo, JJ et al.
z-scores and odds of0.5 change in baseline to follow-up z-scores
were estimated. RESULTS: A total of 1179 eligible patients were
identiﬁed with mean age 15.2 years (SD, 2.16) and 51% female.
The distribution was: FGA’s 19% (n = 253), aripiprazole 11%
(n = 129), olanzapine 15% (n = 182), quetiapine 25% (n = 297),
risperidone 26% (n = 308), and ziprasidone 3% (n = 32). In the
linear model, adolescents on olanzapine experienced a signiﬁcant
increase in BMI [0.84 kg/m2 (CI, 0.17–1.52)] compared to those
on aripiprazole. Logistic model results indicated a signiﬁcant
likelihood of a 5 to 20% increase in BMI for those on olanzapine
[OR: 1.54 (CI, 0.96–2.5) to 4.53 (CI, 1.79–11.48) and a 10 to
20% increase for those on risperidone [OR: 1.84 (CI, 1.15–3.0) to
2.18 (CI, 1.21–3.96)], compared to aripiprazole. In the BMI
z-score analysis, adolescents on olanzapine experienced a signiﬁ-
cant increase in BMI [OR: 1.65 (CI, 1.02–2.67)]. Results for
FGA’s, quetiapine, and ziprasidone were not statistically signiﬁ-
cant. CONCLUSION: Potential for weight gain varies by anti-
psychotics and should be taken into account while prescribing
these medications to adolescents.
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OBJECTIVE: Inhibiting or inducing antipsychotic metabolism
via the hepatic cytochrome P450 (CYP450) may have clinical
and economic consequences. This study examined whether
drug-drug interactions (DDIs) between oral antipsychotics and
non-antipsychotic concomitant medications that are inhibitors or
inducers of CYP450 isoenzymes are associated with increased
health care utilization and costs in schizophrenics or
schizoaffective-disorder patients. METHODS: Ohio State Med-
icaid data contributed patients (18  age < 65) who had schizo-
phrenia or schizoaffective disorder and received an antipsychotic
from 2000 to 2003 (N = 31,716). Clinically signiﬁcant DDI pair-
ings (Facts & Comparisons 4.0) were examined, with concomi-
tant exposure for an antipsychotic prescription overlapping with
an interacting medication. Three adverse events (AEs) (extrapy-
ramidal symptoms, increased seizure risk and QT-prolongation
or arrhythmias) associated with DDIs were studied. Utilization
and costs for inpatient and ambulatory care during a 90-day
follow-up were examined. Regression analyses were used to
adjust for confounding factors between patient groups.
RESULTS: Most patients had non-DDI (26,546); 7060 had a
DDI (no AE) and 110 experienced DDI + AE. Length of stay
and emergency room visits (mean  SD) were highest for DDI +
AE (25 days  17.8; 3.4  4.1) and lower for the DDI
(11 days  9.9; 1.5  1.0) and non-DDI (3.6 days  15.6;
0.5  2.8) groups. Health care costs were higher with DDI + AE
($9699) or DDI ($2962) compared with non-DDI ($2201).
Regression analysis indicated that patients with DDI + AE or
DDI had signiﬁcantly higher health care utilization and costs
than patients without DDI (P < 0.001). Stepwise regression
showed that patients with a DDI or DDI + AE associated with
olanzapine, risperidone and quetiapine had higher total costs
than patients without a DDI. CONCLUSION: These data
suggest that antipsychotic DDIs are related to higher health care
utilization and costs. Efforts to avoid potential DDIs associated
with some antipsychotics are critical for clinical practitioners to
prevent costly clinical and economic consequences.
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OBJECTIVE: Study of depression on disability days and work
absenteeism in patients with chronic medical disorders (CMDs)
is limited. Our objective was to compare annual bed days and
missed workdays in CMD patients with and without depression.
METHODS: For retrospective analysis, we extracted data on
>/=18 year-old employed adults from the pooled 2004–5 Medical
Expenditure Panel Survey. Data included ICD-9-CM-coded
CMD (hyperlipidemia, heart-disease, arthritis/other joint-
disorders, chronic obstructive pulmonary disease, hypertension,
diabetes), and depression; number of missed workdays and bed
days, age, gender, race, poverty level, health insurance, health
status (physical, mental), urban residence, and any depression
treatment (psychotherapy/antidepressant). For 6786 CMD
patients with and without depression, we compared rates with
one or more missed workdays and bed days, and mean number
of missed workdays and bed days. Weighted sample estimates
and 95 percent conﬁdence limits (CL) were calculated using the
Taylor expansion method. In multivariate logistic regression
models, after controlling for other characteristics, we examined
association of depression with one or more missed workdays and
one or more bed days. RESULTS: Compared with those without
depression, signiﬁcantly more CMD patients with depression
reported one or more missed workdays [50.26% (SE0.86%) vs.
70.14% (SE2.11%) p < 0.001], and one or more bed days
[18.51% (SE0.66%) vs. 34.24% (SE2.2%), p < 0.001]. The
mean number of missed workdays (9.93+/-0.94 vs. 5.01+/-0.22)
and bed days (4.29+/-0.62 vs. 1.03+/-0.08) were also higher in
CMD with versus without depression. In multivariate analyses,
after controlling for other characteristics including any depres-
sion treatment, depression increased the likelihood of one or
more missed workdays (adjusted Odds-Ratio, OR 1.41, 95%
CL:1.14–1.75, p = 0.002) and one or more bed days (OR 1.37,
95% CL:1.07–1.75, p = 0.013) in CMD patients. CONCLU-
SION: Depression plays a signiﬁcant role in both absenteeism
and bed days in CMD patients in the United States. Effective
identiﬁcation and treatment strategies require the attention of
both providers and payers.
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OBJECTIVE: Childhood obesity as a known risk factor associ-
ated with bipolar disorder complicates its treatment. The
purpose of this study is to assess treatment costs and comorbidi-
ties associated with obesity in children and adolescents with
bipolar disorder. METHODS: Based on a multi-state managed
care medical claims database (PharMetrics), a total of 9895
children and adolescents (6 < age < 19) who had been diagnosed
and received medication treatment for bipolar disorder during
the period January 1, 1998 to December 31, 2002 were selected
for this study. Annual treatment cost per patient was constructed
as the sum of reimbursed amounts (in 2002 constant dollars) for
hospitalizations, outpatient care, emergency room (ER) visits,
physician encounters, laboratory tests, drugs, and other medical
services. A stepwise log-linear regression analysis was used to
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assess the factors inﬂuencing annual treatment costs. Logistic
regression analysis was conducted to assess the association
between obesity and related clinical factors. RESULTS: A total of
341 (3.4%) children or adolescents received an obesity diagnosis
during the study period. The average annual treatment costs were
$7481 (SD  8371) for patients experiencing obesity and $5364
(SD  15,322) otherwise. A total of 4204 (42.5%) patients
received atypical antipsychotics, 2237 (22.6%) with lithium, and
5890 (59.5%) with other anticonvulsants. Being obesity is asso-
ciated with atypical antipsychotic use (odds ratio [OR] = 1.49,
95% conﬁdence interval [CI] 1.18–1.88), and key comorbidities
like diabetes mellitus (OR = 3.40, 95%CI 1.96–5.89) and hyper-
tension (OR = 4.41, 95%CI 2.70–7.20). Higher treatment cost is
associated with the use of atypical antipsychotics (p < 0.0001),
hospitalization (p < 0.0001), ER visit (p < 0.0001), and some key
comorbidities like diabetes mellitus (p < 0.0001) and substance
abuse disorder (p < 0.0001). CONCLUSION: Higher treatment
costs are associated with obesity in children or adolescents with
bipolar disorder. Metabolic complications should be considered
by clinical practitioners when prescribing medication in this
population.
PODIUM SESSION II
HEALTH CARE DECISION-MAKER’S CASE STUDIES II
CASE 4
THE IMPACT OFTHE PROJECT OF ENHANCING COVERAGE
RATE FOR PATIENTSWITH CANCER
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Organization: Health Insurance Review & Assessment Services
(HIRA), Seoul, Korea.
Problem or Issue Addressed: Policy makers of Korean govern-
ment decided to increase the rate of public expenditure on health
per total expenditure on health (coverage rate) in the patients
with cancer. There had been conﬂicts between health care pro-
viders and decision makers of health insurance in the use of
off-label anticancer drug.
Goals: (1)Stepwise increase coverage rate of the patients with
cancer; (2)Rational control of off-label drug use related to treat-
ment of cancer including chemotherapeutic drugs and drugs for
cancer pain; (3)To control the reimbursement for the patients
with cancer in the limited budget allocation.
Outcomes items used in the decision: Safety and effectiveness
data from the literature and cost of drug.
Implementation Strategy: A Project to enhance coverage rate of
treatment of cancer started in September, 2005. The project
consists of the registry of the patients with cancer, and the special
committee for review of drugs related to treatment of cancer. The
handouts for the meetings have been made according to the
‘evidence based review manual’ which had been made by evi-
dence based health care team of HIRA. It is systematic approach
to retrieve information related to the safety and effectiveness
about the drugs. The rate of the patient’s payment per beneﬁt
schedule is reduced from 20% to 10%.
Results: The total number of patients whose medical fees were
claimed by health care provider was 42.8 million in 2005 and it
was 43.4 million in 2006 increased by 1.4%. The total number of
patients with cancer among them was 670 thousands in 2005
and it was 710 thousands in 2006, increased by 6.0%. The rate
of public expenditure on health per total expenditure on health in
the patients with cancer increased from 49.6% to 71.0%. The
rate of patients taken with anticancer chemotherapy increased
from 5.9% to 7.9%. The expected allocated budget was 597
million $ and the actual spending money was 524 million $. The
conﬂicts about off-label drug use have decreased.
Lessons Learned: The project was performed successfully by
evidence based decision making process and reasonable use of off
label drug use.
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Problem or Issue Addressed: The Pharmacy Cost Management
Committee of the Partners Healthcare System (PHS), a consor-
tium of seven greater Boston area hospitals, has recognized the
need to control the future growth rate of pharmaceuticals by
managing the utilization of new, high cost pharmaceutical tech-
nologies and learning from best practices across the network and
country. The Center for Drug Policy (CDP) was established in
August 2007 to provide the analytical resources to support the
Pharmacy Directors and multidisciplinary teams of physician and
pharmacist content experts in this endeavor.
Goals: The major objectives of the CDP are to forecast and
manage the introduction of new, high cost pharmaceutical tech-
nologies and to streamline the development and implementation
of common guidelines across the network. Additional objectives
of the CDP are to 1) identify and coordinate cost savings oppor-
tunities, 2) conduct prospective utilization reviews and assess-
ment, 3) share best practices across the network, and 4)
benchmark against high performance organizations nationwide.
Outcomes items used in the decision: Both process and outcome-
related measures will be measured. For process-related measures,
the number of the following outputs and select intermediate
steps will be assessed quarterly: guidelines (drug/therapeutic
class/disease), budget-impact models, guideline dissemination
and implementation, and assessment of guideline impact.
Outcome-related measures will be assessed at a global level and
a project-speciﬁc level. At the global level, annual drug pur-
chases, drug cost/case-mix adjusted discharge, and drug cost/
case-mix adjusted patient day will be measured quarterly at each
hospital. At a project-speciﬁc level, outcomes will depend on the
pharmaceutical technology but would include clinical (e.g.,
adherence to guidelines, time to event, complications, etc.) and
economic measures (e.g., volume of drug, length of stay, drug
purchases, etc.)
Implementation Strategy: To establish the CDP, the CDP leader-
ship met with key stakeholders across the network of hospitals,
undertook a targeted literature review of cost management strat-
egies in the hospital setting, and conducted an on-site visit to
another hospital’s CDP. Access to and training on key data
resources including drug purchasing data, computerized physi-
cian order entry, and cost accounting systems was obtained. A
database to track emerging drug therapies and tools to assist in
project management were created. Internal processes and tools
were developed to ensure quality, consistency, and documenta-
tion of guideline development. To facilitate sharing best practices
across the hospital network, presentation opportunities have
been provided at monthly CDP meetings; in addition, a monthly
memo summarizing key Pharmacy & Therapeutics Committees
activities across the network has been prepared and distributed
to Pharmacy leadership. Templates for ongoing internal report-
ing were also developed.
Results: As the CDP was established in August 2007, data col-
lection is ongoing; an overview of anticipated results is, however,
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